Gillessen et al. [50] confirmed in a large retrospective evaluation of 107,859 patients with prostate cancer that patients treated with Gonadotrophin-releasing hormone (GnRH) antagonist or orchiectomy presented an increase of 30-40% risk of developing CRC when compared to the subgroup that were not submitted to androgenic deprival. This evidence concerns the gene GNRH1 and colorectal carcinoma.